CN105893782A - Prostatic cancer risk predicting device - Google Patents
Prostatic cancer risk predicting device Download PDFInfo
- Publication number
- CN105893782A CN105893782A CN201610354733.4A CN201610354733A CN105893782A CN 105893782 A CN105893782 A CN 105893782A CN 201610354733 A CN201610354733 A CN 201610354733A CN 105893782 A CN105893782 A CN 105893782A
- Authority
- CN
- China
- Prior art keywords
- prostate
- result
- user
- module
- prostatic cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Data Mining & Analysis (AREA)
- Databases & Information Systems (AREA)
- Pathology (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Primary Health Care (AREA)
- Measuring And Recording Apparatus For Diagnosis (AREA)
Abstract
The invention discloses a prostatic cancer risk predicting device which comprises an information collecting module, a risk predicting module and a result feedback module. The information collecting module is used for receiving related information and an examination result of a user, the risk predicting module is used for receiving data of the information collecting module, and the result feedback module is used for feeding a result of the risk predicting module back to the user and medical staff. The prostatic cancer risk predicting device is based on a prostatic risk predicting model suitable for Chinese people, so that early prediction of prostatic cancer risk of a patient is facilitated, and the prostatic cancer risk predicting device can prompt prostatic puncture biopsy as soon as possible; in addition, the prostatic cancer risk predicting device can realize background data collection and brings convenience to the medical staff to know information of the patient in details and to diagnosis and treatment. The prostatic cancer risk predicting device is wide in application range, the patient fills in information according to needs completely, and risk value of current prostatic cancer of individuals can be predicted; contact information can be further filled in for the convenience of contact between the medical staff and the patient. The prostatic cancer risk predicting device has great public health significance and economic value.
Description
Technical field
The present invention relates to a kind of individual level carcinoma of prostate detection risk forecast model, belong to preventive medicine in medical domain
Field.
Background technology
Carcinoma of prostate alreadys more than pulmonary carcinoma at the sickness rate of the U.S., becomes the tumor of first harm men's health.According to U.S.
Cancer association of state estimates, within 2013, newly sends out carcinoma of prostate in the U.S. about 238 590 example, has 29 720 examples will die from this sick.
In Europe, obtaining new cases for prostate cancer about 2,600,000 people made a definite diagnosis every year, carcinoma of prostate accounts for whole male cancer number
11%, account for the 9% of whole male cancer deaths number.The sickness rate of Asia carcinoma of prostate is less than American-European countries, but in recent years
Present ascendant trend.Patients with prostate cancer is mainly elderly men, and new diagnosis patient's the median age is 72 years old, and the peak age is 75
～79 years old.In the U.S., the patients with prostate cancer age more than 70% is above 65 years old, and the right side of fifty male is rarely found, but greatly
In 50 years old, M & M will be exponentially increased.The age individuality less than 39 years old, the probability suffering from carcinoma of prostate is
Within 0.005%, 40～59 year old, age bracket increases to 2.2% (1/45), 60～79 years old age bracket increase to 13.7% (1/7).
Carcinoma of prostate make a definite diagnosis the Diagnosis of Prostatic Carcinoma by Aspiration Biopsy depending on various path more, for traumatic examination, inapplicable
In the examination of carcinoma of prostate, for EARLY RECOGNITION carcinoma of prostate, need efficient examination means.Early prostate cancer is usually not
Symptom, during to advanced tumor infringement or urethral obstruction, neck of bladder, it may occur that similar lower urinary tract obstruction or irritation, severe patient
It is likely to occur acute urinary retention, hematuria, urinary incontinence.Skeleton pain, pathologisch Bruch, anemia, spinal cord pressure can be caused during Bone tumour
Compel to cause lower extremity paralysis etc., so prostate cancer symptoms cannot function as early screening means.Instantly, the early screening of carcinoma of prostate
Depend on serum PSA (prostate-specific antigen, PSA) to check more.But, prostate increases
Raw and carcinoma of prostate etc. also may cause PSA to raise, the low specificity of hypersensitivity checked in view of PSA, has scholar to write articles query
Although PSA examination improves recall rate, but does not reduce mortality rate, bring the problems such as excessive diagnosis and treatment on the contrary.The most extensively fortune
PSA threshold value be 4ng/ml, if single with PSA > 4ng/ml for puncturing indication, the most unnecessary puncture can be caused so that big
Amount patient suffers unnecessary misery and risk.In view of the low specificity of PSA examination carcinoma of prostate, the index of some improvement is such as
PSAD, f/T are applied to clinic, but because these indexs all rely on PSA, so diagnosis efficiency improves limited.
Improving prostate cancer screening efficiency, EARLY RECOGNITION carcinoma of prostate high-risk group, in time row prostate biopsy checks,
Reduce unnecessary puncture, be to contain the key point that human health is threatened by carcinoma of prostate.At present, everybody generally believes individuality
Level math Model Identification carcinoma of prostate high-risk group is effective instrument, can improve prostate cancer screening efficiency, for clinic
Treatment provides valuable information, is also disease prevention simultaneously, and government decision and health program scheme works evaluation ratio can not
Few instrument.First foreign scholar has carried out similar research, it is proposed that based on multiple high risk factor such as lab testing, B ultrasonic figure
As, refer to examine the forecast model of the foundation such as result, and show standard higher in terms of prostate cancer diagnosis in corresponding crowd
Really property, thus avoid the puncture that part is unnecessary.But, due to differences such as ethnic group, whole medical treatment level and living habit, across
The forecast model of region and ethnic group often accuracy ratio is relatively low.Even if the most famous state's external model is when Chinese population is applied,
Its specificity and sensitivity also can significantly reduce.
At present, China's Mainland there is no carcinoma of prostate based on sample size detection risk model foundation.Additionally, existing model
Cannot the result of feedback forecasting in time during utilization so that patient cannot contact in time with medical institutions.
Summary of the invention
Technical problem: the present invention provides the prostate cancer risk prediction means of a kind of simple, intuitive based on wechat platform,
Carcinoma of prostate high-risk group can be detected well, as early as possible high-risk group is carried out prostate biopsy, early detection carcinoma of prostate,
Early treatment；Get rid of carcinoma of prostate low danger crowd so that it is from prostate biopsy.
Technical scheme: the prostate cancer risk prediction means of the present invention, including:
Information acquisition module, in order to receive the relevant information of user and to check result；
Risk profile module, in order to receive the data of information acquisition module, and calculates user according to following formula and suffers from cancer risk:
Wherein, a is the age, and b is fPSA value/PSA value, c=ln(prostate volume), d=ln(PSA value), e, for referring to inspection result, refers to
Inspection has exception, takes 0, refers to examine and normally takes 1, and f is prostate ultrasound diagnosis result, is found to have the low echo of peripheral zone and takes 0, the most then takes
1；
Result feedback module, in order to feed back to user and hospital personnel by the result of risk profile module.
Further, in apparatus of the present invention, relevant information and the inspection result of described user include: the user age,
Whether whether prostate specific antigen, PSA, prostate volume, digital rectal examination have anomaly, prostate ultrasound diagnosis
It is found to have the low echo of peripheral zone.
The prostate cancer risk forecast model that the present invention sets up based on Chinese population large sample, implements by wechat platform,
Greatly facilitate the early screening of carcinoma of prostate, and facilitate diagnosis and treatment process.
Use apparatus of the present invention, can be the most fast and easily according to own actual situation inquiry oj C prostate cancer
Risk, and set up and can obtain feedback information in time by platform, convenient user information of collecting contacts, and reduces on the whole
The carcinoma of prostate harm to human health.
The specifically used of apparatus of the present invention comprises the following steps:
S1: set up wechat model platform and the background server of service side
S2: wechat service platform utilizes wechat to accept the relevant information that user provides
S3: wechat service platform calls background server calculation procedure according to the information accepted, and calculates
Final calculation result (and carcinoma of prostate risk) is fed back to user by S4: wechat service platform
S5: wechat service platform provides link to fill in more information for user
S6: background server storage the filled out information of user
Before step S2, also include step S11, described step S11 be set up belonging to wechat service platform wechat public number or
Subscription number, and wechat public number or subscription number are directly published on wechat service platform, and can be by creating respective two-dimensional code
Convene user.
Beneficial effect: the present invention compared with prior art, has the advantage that
The PSA threshold value the most extensively used is 4ng/ml, if single with PSA > 4ng/ml for puncturing indication, owing to there is more false sun
Property patient, the most unnecessary puncture can be caused so that a large amount of patients suffer unnecessary misery and risk.The present invention is measurable
Carcinoma of prostate risk, thus improve prostate cancer screening efficiency, can be with EARLY RECOGNITION carcinoma of prostate high-risk group, appropriateness
Carry out prostate biopsy inspection, reduce unnecessary puncture, save a large amount of medical resource.
Model is set up based on large sample Chinese patients data, is therefore applicable to Chinese ethnic group.First foreign scholar carries out
Similar research, it is proposed that based on multiple high risk factor such as lab testing, B ultrasonic image, refer to examine the forecast model of the foundation such as result,
And show accuracy higher in terms of prostate cancer diagnosis in corresponding crowd, thus avoid unnecessary the wearing of part
Thorn.But, owing to the forecast model of difference, cross-region and the ethnic groups such as ethnic group, whole medical treatment level and living habit is the most accurate
Property is relatively low.Even the most famous state's external model applies its specificity and sensitivity also can significantly reduce at Chinese population.With
Abroad risk forecast model is not strong to the domestic people suitability, and cannot popularize.And this model is based entirely on Chinese ethnic group number
According to, and required detection is the most easy, has preferable popularization and the suitability.
After user of the present invention uses, prostate can be suffered from according to own actual situation inquiry the most fast and easily
The risk of cancer.Ruck carries out risk profile by this device, improves anti-cancer consciousness.Additionally, this device contributes to medical treatment
, according to result immunotherapy targeted autoantibody, there is important public hygienics meaning in mechanism.
Foundation side (such as medical worker) can obtain feedback information in time by platform, and convenient user information of collecting joins
System, and for further study.And avoid traditional registering, outpatient service and accept old process such as being admitted to hospital for medical treatment, directly can contact with patient,
And further diagnosis and treatment project is provided, significantly facilitate doctor and patient diagnosis and treatment process.
Accompanying drawing explanation
Fig. 1 is flow chart of the present invention.
Detailed description of the invention
Below in conjunction with embodiment and Figure of description, the present invention is further illustrated.
The embodiment of prostate cancer risk prediction means of the present invention, source self centeredness retrospective study 1104 example PSA >
4.0ng/ml also accepts the data that option of prostate biopsy guided by transrectal ultrasound is individual.The itemized record age, PSA, fPSA,
PV, digital rectal examination and B ultrasonic result, and derivative calculate the variablees such as f/t, PSA density (PSAD).Use multivariate logistic regression subsequently
Analysis and Screening has the risk forecast model that significant factors is set up.
Described data change into the concrete transform mode of recognizable data: Age is the input age；F/t is fPSA and PSA
Ratio；Ln(PV) it is that prostate volume takes natural logrithm；Ln(PSA) it is that PSA takes natural logrithm；DRE findings is rectum
Referring to inspection result, the value that notes abnormalities is not 1, not and abnormal value 0；Hypoechoic is ultrasound diagnosis peripheral zone low echo result, sends out
Existing peripheral zone low echo value is 1, has no that low echo value is 0.
User directly can see predicted result in wechat public number in real time.And can continue as required
Input self information, facilitates medical worker to obtain details.
As it is shown in figure 1, the carcinoma of prostate risk prediction means of the present invention, including information acquisition module, in order to receive
The relevant information of user and inspection result, wherein relevant information and the inspection result of user includes: user age, prostatitis
Whether gland specific antigen, PSA, prostate volume, digital rectal examination have whether anomaly, prostate ultrasound diagnosis find
There is the low echo of peripheral zone；
Risk profile module, in order to receive the data of information acquisition module, and calculates user according to following formula and suffers from cancer risk:
Wherein, a is the age, and b is fPSA value/PSA value, c=ln(prostate volume), d=ln(PSA value), e, for referring to inspection result, refers to
Inspection has exception, takes 0, refers to examine and normally takes 1, and f is prostate ultrasound diagnosis result, is found to have the low echo of peripheral zone and takes 0, the most then takes
1；
Result feedback module, in order to feed back to user and hospital personnel by the result of risk profile module.
Based on result feedback module, user directly can see predicted result in wechat public number in real time.And
Self information can be continued with as required, facilitate medical worker to obtain details.
The use embodiment of apparatus of the present invention is:
S1: set up wechat model platform and the background server of service side.Service side's wechat model platform relies on " prostate ten thousand
Thing room " public number, background server can provide risk forecast model to calculate；
S2: wechat service platform utilizes wechat to accept the relevant information that user provides.Patient logs in after wechat enters public number,
Can input as requested or select, it is provided that relevant information.
S3: wechat service platform calls background server calculation procedure according to the information accepted, and calculates.Background service
Accepted information is converted into computable number evidence by device, brings risk forecast model into and calculates, obtains a result.
Final calculation result (and carcinoma of prostate risk) is fed back to user by S4: wechat service platform.Assume one
User input and the information selected are " 70 years old ", " PSA 6.5ng/ml ", and " prostate volume 55mm*50mm*40mm " is " straight
Intestinal refers to inspection feminine gender ", " prostate B ultrasonic is without low echo ", and " without special circumstances ".After clicking on " submission information ", automatically show
Going out result of calculation, result is carcinoma of prostate positive rate: 15.9%, in high-risk tumor probability: 25.4%.
S5: wechat service platform provides link to fill in more information for user.On result interface, user can continue defeated
Enter relevant information: name, contact method and contact address.
S6: background server storage the filled out information of user.Set up service side and can derive user input by backstage
Data, convenient contact patient also provides further diagnosis and treatment.
Further, service side can be by setting up the use of corresponding Quick Response Code Rate Based On The Extended Creep Model, and user may utilize scanning two
The mode of dimension code joins in wechat public number or subscription number, hence into this wechat service platform.
The present embodiment user can inquire about oj C prostate cancer according to own actual situation the most fast and easily
Risk, platform provider can conveniently collect user information with for further study.
Above-described embodiment is only the preferred embodiment of the present invention, it should be pointed out that: for those skilled in the art
For, under the premise without departing from the principles of the invention, it is also possible to make some improvement and equivalent, these are to right of the present invention
Require improve with equivalent after technical scheme, each fall within protection scope of the present invention.
Claims (2)
1. a prostate cancer risk prediction means, it is characterised in that this device includes:
Information acquisition module, in order to receive the relevant information of user and to check result；
Risk profile module, in order to receive the data of information acquisition module, and calculates user according to following formula and suffers from cancer risk:
Wherein, a is the age, and b is fPSA value/PSA value, c=ln(prostate volume), d=ln(PSA value), e, for referring to inspection result, refers to
Inspection has exception, takes 0, refers to examine and normally takes 1, and f is prostate ultrasound diagnosis result, is found to have the low echo of peripheral zone and takes 0, the most then takes
1；
Result feedback module, in order to feed back to user and hospital personnel by the result of risk profile module.
Prostate cancer risk prediction means the most according to claim 1, it is characterised in that the relevant information of described user
And check that result includes: whether user age, prostate specific antigen, PSA, prostate volume, digital rectal examination have
Whether anomaly, prostate ultrasound diagnosis are found to have the low echo of peripheral zone.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610354733.4A CN105893782A (en) | 2016-05-26 | 2016-05-26 | Prostatic cancer risk predicting device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610354733.4A CN105893782A (en) | 2016-05-26 | 2016-05-26 | Prostatic cancer risk predicting device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105893782A true CN105893782A (en) | 2016-08-24 |
Family
ID=56716899
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610354733.4A Pending CN105893782A (en) | 2016-05-26 | 2016-05-26 | Prostatic cancer risk predicting device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105893782A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108461148A (en) * | 2018-03-30 | 2018-08-28 | 张淼 | A kind of small routine of screening cancer |
| CN112450982A (en) * | 2020-12-09 | 2021-03-09 | 上海市闵行区中心医院 | Qualitative and data scoring system for predicting prostate cancer through B-ultrasonic expression |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101220392A (en) * | 2006-10-31 | 2008-07-16 | 维里德克斯有限责任公司 | Characterizing prostate cancer |
| CN102301002A (en) * | 2008-11-12 | 2011-12-28 | 卡里斯生命科学卢森堡控股有限责任公司 | Methods and systems of using exosomes for determining phenotypes |
| CN102482711A (en) * | 2009-01-07 | 2012-05-30 | 美瑞德生物工程公司 | Cancer biomarkers |
| CN102549167A (en) * | 2009-05-12 | 2012-07-04 | 皇家飞利浦电子股份有限公司 | Phosphodiesterase 4d7 as prostate cancer marker |
| CN104364788A (en) * | 2012-03-05 | 2015-02-18 | 阿克蒂克合伙公司 | Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume |
-
2016
- 2016-05-26 CN CN201610354733.4A patent/CN105893782A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101220392A (en) * | 2006-10-31 | 2008-07-16 | 维里德克斯有限责任公司 | Characterizing prostate cancer |
| CN102301002A (en) * | 2008-11-12 | 2011-12-28 | 卡里斯生命科学卢森堡控股有限责任公司 | Methods and systems of using exosomes for determining phenotypes |
| CN102482711A (en) * | 2009-01-07 | 2012-05-30 | 美瑞德生物工程公司 | Cancer biomarkers |
| CN102549167A (en) * | 2009-05-12 | 2012-07-04 | 皇家飞利浦电子股份有限公司 | Phosphodiesterase 4d7 as prostate cancer marker |
| CN104364788A (en) * | 2012-03-05 | 2015-02-18 | 阿克蒂克合伙公司 | Methods and apparatuses for predicting risk of prostate cancer and prostate gland volume |
Non-Patent Citations (1)
| Title |
|---|
| YUAN HUANG等: "A prostate biopsy strategy based on a new clinical nomogram reduces the number of biopsy cores required in high-risk patients", 《BMC UROLOGY 2014》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108461148A (en) * | 2018-03-30 | 2018-08-28 | 张淼 | A kind of small routine of screening cancer |
| CN112450982A (en) * | 2020-12-09 | 2021-03-09 | 上海市闵行区中心医院 | Qualitative and data scoring system for predicting prostate cancer through B-ultrasonic expression |
| CN112450982B (en) * | 2020-12-09 | 2023-03-28 | 上海市闵行区中心医院 | Qualitative and data scoring system for predicting prostate cancer through B-ultrasonic expression |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Bozkurt et al. | Using automatically extracted information from mammography reports for decision-support | |
| Ibfelt et al. | Socioeconomic position and stage of cervical cancer in Danish women diagnosed 2005 to 2009 | |
| Williams et al. | Identifying persons at highest risk of melanoma using self-assessed risk factors | |
| Untiet et al. | HPV self‐sampling as primary screening test in sub‐Saharan Africa: implication for a triaging strategy | |
| Hunt et al. | Diagnosing cervical neoplasia in rural Brazil using a mobile van equipped with in vivo microscopy: A cluster-randomized community trial | |
| Ren et al. | Factors correlated with the accuracy of colposcopy-directed biopsy: a systematic review and meta-analysis | |
| Rosa-Cunha et al. | Description of a pilot anal pap smear screening program among individuals attending a Veteran's Affairs HIV clinic | |
| Philp et al. | Pap tests in the diagnosis of cervical cancer: help or hinder? | |
| Östensson et al. | Projected cost‐effectiveness of repeat high‐risk human papillomavirus testing using self‐collected vaginal samples in the Swedish cervical cancer screening program | |
| Nodjikouambaye et al. | A systematic review of self‐sampling for HPV testing in Africa | |
| CN113393938B (en) | Breast cancer risk prediction system fusing image and clinical characteristic information | |
| Hunt et al. | Cervical lesion assessment using real‐time microendoscopy image analysis in Brazil: the CLARA study | |
| Song et al. | Automatic recognition of uterine contractions with electrohysterogram signals based on the zero-crossing rate | |
| Goldstein et al. | Assessing the feasibility of a rapid, high-volume cervical cancer screening programme using HPV self-sampling and digital colposcopy in rural regions of Yunnan, China | |
| Chang et al. | Incidence and costs of cervical intraepithelial neoplasia in the Korean population | |
| Khondker et al. | A machine learning-based approach for quantitative grading of vesicoureteral reflux from voiding cystourethrograms: Methods and proof of concept | |
| Cholkeri-Singh et al. | Digital colposcopy with dynamic spectral imaging for detection of cervical intraepithelial neoplasia 2+ in low-grade referrals: the IMPROVE-COLPO study | |
| CN105893782A (en) | Prostatic cancer risk predicting device | |
| Aiello et al. | Rate of breast cancer diagnoses among postmenopausal women with self-reported breast symptoms | |
| Wang et al. | Development and validation of a novel diagnostic nomogram model to predict primary aldosteronism in patients with hypertension | |
| DeNardis et al. | Increased detection of precancerous cervical lesions with adjunctive dynamic spectral imaging | |
| Kuhrt et al. | Endocervical and high vaginal quantitative fetal fibronectin in predicting preterm birth | |
| Sanderson et al. | Mammography screening among the elderly: a research challenge | |
| CN207270333U (en) | A kind of multi-modal Breast health detecting system | |
| Founta et al. | Diagnostic accuracy of colposcopy with dynamic spectral imaging for cytology-negative/high-risk HPV positive (failed test of cure) after large loop excision of the transformation zone (LLETZ) of the cervix: results of the DySIS colposcopy 1 study |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160824 |
|
| RJ01 | Rejection of invention patent application after publication |